Eisai EMEA
A Marketer's Guide to Strategically Promoting Oncology Innovation
Jaime Manzanera Gómez
Jaime Manzanera Gómez is a seasoned professional with over 16 years of multifaceted experience spanning marketing, sales and strategic leadership in the pharmaceutical segment. Transitioning from roles as varied as brand and marketing manager to national sales manager and eventually global brand manager at Leo Pharma, he has demonstrated a keen ability to navigate diverse markets across continents.
Currently serving as Regional Brand Director of Oncology at Eisai EMEA, Jaime oversees pharmaceutical strategy formulation for genitourinary cancers across the EMEA region. He leverages his rich understanding of global dynamics and cultural nuances to drive impactful outcomes in the international oncology and pharma landscapes.
In an interview with Life Sciences Review Europe, Jaime Manzanera Gómez shares his valuable insights into the current trends shaping the oncology landscape and suggests tips for fellow marketers and strategists.
What are some of the challenges in the oncology space that you have recently witnessed, and how can these be addressed?
In our stringently regulated industry, compliance is paramount for successful promotion and commercial activities. It's essential to acknowledge that promoting directly to the general public is prohibited, which means the focus should be on engaging healthcare professionals.
Furthermore, product messaging must align with proven evidence in accordance to regional laws, a prerequisite integrated into the Summary of Product Characteristics (SPC) for every medication. This consideration underscores the importance of a structured and rule-bound approach in marketing therapeutic products, especially acknowledging the limitations in promotional activities that vary across countries.
The impact of General Data Protection Regulation (GDPR) adds another layer of complexity, especially for a sector deeply rooted in traditional customer interactions spanning decades. The need to collect consents has introduced a new barrier, challenging established ways of operating. This is particularly significant as the pharmaceutical industry finds itself trailing behind in the adoption of omnichannel strategies.
While strides have been made, achieving an optimal omnichannel workflow remains a considerable challenge. The industry is still navigating the early stages of integrating these approaches into our daily operations. Addressing these challenges and finding innovative solutions will be crucial for the industry's evolution in a rapidly changing digital landscape.
Can you specify some current technologies or trends that are prevailing in the pharmaceutical industry?
The advent of immuno-oncology has revolutionized how we approach and manage cancer. These therapies have exceeded expectations by offering unprecedented outcomes, with patients experiencing long-term complete remissions—a remarkable shift, particularly in stage four or metastatic cases.
On-going research in immuno-oncology is extending beyond traditional boundaries, exploring its efficacy in less advanced stages. Investigations into adjuvant and neo-adjuvant settings are showing promising results. The exploration of new targets and combinations, such as checkpoint inhibitors paired with various pathways, further aims to enhance the immune system's effectiveness. It has the potential to achieve complete responses or even transforming cancer into a manageable chronic condition.
Building close relationships with key customers and salespeople are paramount, as it provides invaluable insights for effective product positioning and strategy development
The field of oncology is witnessing a surge in breakthrough therapies, including Antibody Drug Conjugates (ADCs) that deliver chemotherapy specifically to tumor cells. These are instrumental in the notable advancements observed in breast cancer management. RNA vaccines, demonstrated to be effective in areas like melanoma when combined with checkpoint inhibitors, showcase another promising avenue.
CAR T-cell therapy, originally designed for liquid tumors, is demonstrating noteworthy efficacy in solid tumors. Looking ahead, CRISPR technology holds immense potential, offering a glimpse into the future of gene editing for addressing critical mutations that drive cancer development.
The advent of artificial intelligence (AI) is reshaping industries the pharmaceutical industry with transformative possibilities. In healthcare, AI is accelerating diagnostics and treatment planning by swiftly analyzing vast datasets, providing healthcare professionals with more accurate and efficient insights. This enhances disease management and holds promise in advancing drug development.
As these innovative developments unfold, the oncology landscape is set to undergo transformative changes in the coming years.
What advice you have for other leaders working in the industry?
For marketers and strategy-setting professionals in the pharmaceutical industry, building close relationships with key customers and salespeople is paramount. Understanding the challenges they face daily, especially in complex patient management situations, provides invaluable insights for effective product positioning and strategy development.
Keep in mind that simplicity is key in communication and strategy. Avoid lengthy presentations with unclear objectives. Instead, focus on clear, concise messages to ensure the strategy resonates effectively.
Lastly, avoid analysis paralysis to prevent the trap of getting stuck in extensive analyzing that may not yield practical outcomes. While numerous information sources exist, overcomplicating models from the start can hinder progress. Start with the basics, test, iterate, and build upon success.
